News Releases


June 8, 2021

Processa Set to Join Russell Microcap® Index

June 7, 2021

Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET

June 1, 2021

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 20, 2021

Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo- Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

May 18, 2021

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 13, 2021

Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update

May 7, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update

March 25, 2021

Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update

March 22, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET

March 17, 2021

Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

March 1, 2021

Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement

February 17, 2021

Processa Pharmaceuticals Announces $10.2 Million Strategic Financing

January 11, 2021

Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

November 16, 2020

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa's pipeline includes several clinical-stage drug candidates

November 12, 2020

Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update

November 5, 2020

Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

November 2, 2020

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update

October 13, 2020

Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer

October 6, 2020

Processa Pharmaceuticals Closes $19.2 Million Public Offering

October 2, 2020

Processa Pharmaceuticals Announces Pricing Of $19.2 Million Public Offering And Uplisting To The Nasdaq Capital Market

August 27, 2020

Processa Pharmaceuticals Entered Into A Contingent Precedent In-Licensing Agreement With Elion Oncology For The Development Of Eniluracil (Pcs6422) For The Treatment Of Advanced Gastrointestinal Tumors

August 20, 2020

Processa Pharmaceuticals Enters Into A Licensing Agreement With Yuhan Corporation For The Development Of Yh12852 In Functional Gastrointestinal Disorders

March 30, 2020

Processa Pharmaceuticals To Move Forward With A Pcs499 Phase 3 Trial After A Successful Fda Meeting

March 17, 2020

Processa Pharmaceuticals Announces Results From The Phase 2 Study In Necrobiosis Lipoidica

March 5, 2020

Processa Pharmaceuticals Announces Formation of its Medical and Scientific Advisory Board

February 25, 2020

Processa Pharmaceuticals Provides Shareholder Update

February 13, 2020

Processa Pharmaceuticals Appoints Geraldine Pannu As An Independent Director To The Board Of Directors

December 20, 2019

Processa Pharmaceuticals Announces 1 For 7 Reverse Stock Split Of Its Common Stock

December 4, 2019

Processa Pharmaceuticals Provides An Update On Positive Results From PCS-499 Phase 2 Trial

September 3, 2019

Processa Pharmaceuticals Announces The Licensing Of An Anti-Fibrotic, Anti-Inflammatory Drug For The Treatment Of Multiple Unmet Medical Need Conditions

August 26, 2019

Processa Pharmaceuticals Announces Last Patient Enrolled In Clinical Trial To Evaluate The Safety And Tolerability Of Pcs-499 For The Treatment Of Necrobiosis Lipoidica

July 15, 2019

Processa Pharmaceuticals Provides A Study Update For Its On-Going Phase 2 Safety And Tolerability Clinical Trial Of PCS-499

May 20, 2019

Processa Pharmaceuticals Announces Today That They Will Be Presenting At The Jeffries 2019 Global Healthcare Conference On Friday, June 7th, 2019

March 11, 2019

Processa Pharmaceuticals Announces Today That They Will Be Presenting At The Cowen Conference On Wednesday

January 29, 2019

Processa Pharmaceuticals Announces First Patient Dosed In Clinical Trial To Evaluate The Safety And Tolerability Of Pcs-499 For The Treatment Of Necrobiosis Lipoidica

January 9, 2019

Processa Pharmaceuticals Amounces Presentation of PCS499 Data at the Annual Meeting of American Academy of Dermatology

December 6, 2018

Processa Pharmaceuticals Announces Up-listing to OTCQB Market

October 2, 2018

Processa Pharmaceuticals Receives Fda Clearance Of Ind To Begin Phase 2 Clinical Development Of Pcs-499 In Necrobiosis Lipoidica Patients

September 10, 2018

Processa Pharmaceuticals Appoints James Stanker As Chief Financial Officer

June 22, 2018

Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)

June 1, 2018

Processa Pharmaceuticals Raises $6.88 Million from Pivate Placements

May 29, 2018

Processa Pharmaceuticals, Inc. to Present at the 8th Annual LD Micro Invitational

Mar 22, 2018

Processa licenses compound from Concert

Mar 21, 2018

Processa Pharmaceuticals Has Been Assigned The License For The Clinical Stage Compound Ctp-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions

Mar 3, 2018

Processa Pharmaceuticals Announces Attendance at 2018 ROTH Conference
> Download Processa Pharmaceuticals Roth Conference Presentaiton

Dec 11, 2017

Processa Pharmaceuticals Announces Reverse Stock Split and Launches New Website

Oct 5, 2017

Heatwurx, Inc. Closes Asset Purchase Transaction with Promet Therapeutics, LLC

Oct 3, 2017

Heatwurx, Inc. Announces Execution Of Definitive Asset Purchase Agreement With Promet Therapeutics, LLC

July 17, 2017

Heatwurx Announces Letter Of Intent With Promet Therapeutics, LLC Relating To A Reverse Merger